WEC
SRNE

Winslow Evans & Crocker’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Winslow Evans & Crocker’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$7K Hold
1,000
– – ﹤0.01% 1030
2020
Q3 		$11K Hold
1,000
– – ﹤0.01% 738
2020
Q2 		$6K Buy
+1,000
New +$3.83K ﹤0.01% 865

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Winslow Evans & Crocker's SRNE Position: Q4 2020 in Review

Winslow Evans & Crocker held its Sorrento Therapeutics, Inc. (SRNE) position steady in Q4 2020 at 1,000 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #1030.

Winslow Evans & Crocker first reported a position in SRNE in Q2 2020 and has held it in 3 quarters since. The position peaked at $11K in Q3 2020. 219 funds tracked by Wall St. Rank hold SRNE as of Q4 2020.

  • Winslow Evans & Crocker held 1,000 shares of Sorrento Therapeutics, Inc. worth $7K as of Q4 2020.
  • Winslow Evans & Crocker left its Sorrento Therapeutics, Inc. share count unchanged in Q4 2020.
  • Sorrento Therapeutics, Inc. made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #1030 holding.
  • Winslow Evans & Crocker first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and has held it in 3 quarters since.
  • Winslow Evans & Crocker's Sorrento Therapeutics, Inc. position peaked at $11K in Q3 2020.
  • 219 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.